Clazosentan for patients with subarachnoid haemorrhage: Lessons learned

The Lancet Neurology

Volumn 10, Issue 10, 2011, Pages 871-

  Wong, George Kwok Chu ^a   Poon, Wai Sang ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CLAZOSENTAN; NIMODIPINE; PLACEBO;

ADVERSE OUTCOME; BRAIN INFARCTION; BRAIN ISCHEMIA; DRUG EFFECT; DRUG EFFICACY; GLASGOW OUTCOME SCALE; HUMAN; LETTER; MORBIDITY; MORTALITY; NEUROPROTECTION; PRIORITY JOURNAL; RISK FACTOR; SUBARACHNOID HEMORRHAGE; SURGICAL TECHNIQUE; TREATMENT DURATION; VASOSPASM;

EID: 80052980673     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70189-2     Document Type: Letter

References (6)

1. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011, 10:618-625.
2. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008, 39:3015-3021.
3. Wong GK, Poon WS, Chan MT, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized double-blinded placebo-controlled multicenter phase III trial. Stroke 2010, 41:921-926.
4. Sabri M, Ai J, Macdonald RL Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan. Stroke 2011, 42:1454-1460.
5. Alaraj A, Wallace A, Mander N, et al. Outcome following symptomatic cerebral vasospasm presentation in aneurysmal subarachnoid hemorrhage: coiling vs. clipping. World Neurosurg 2010, 74:138-142.
6. Wong GK, Poon WS, Boet R, et al. Health-related quality of life after aneurysmal subarachnoid hemorrhage: profile and clinical factors. Neurosurgery 2011, 68:1556-1561.